Stem Cell Therapy Treatment for Multiple Sclerosis Approved by FDA for Stage I Clinical Trial

In an exciting new development, the Food and Drug Administration (FDA) has approved a new stem cell-derived treatment for a phase I clinical trial in the treatment of multiple sclerosis (MS). This FDA approval is the culmination of more than a decades worth of research into the therapeutic potential of stem cells for MS patients by the stem cell research division of the Tisch Multiple Sclerosis Research Center of New York. The first of its kind in the United States, the study will initially enroll 20 progressive MS patients, recruited from the existing patient population of the International Multiple Sclerosis Management Practice, who will have specialized neural progenitor cells injected into their cerebrospinal fluid in order to directly target regenerative mechanisms in the central nervous system. Saud Sadiq, Director of TMSRC, collaborates with NYSCF's multiple sclerosis team, led by Dr. Valentina Fossati, by recruiting patient participants for Dr. Fossati’s work generating stem cells from MS patients.


Read the Tish MS Research Center press release >>

Read more on NYSCF's MS research >>